Recent evidence reveals that more patients could benefit from receiving a continuous glucose monitoring prescription as part of diabetes care from their primary provider.

Key market opportunities include increasing adoption of OTC continuous glucose monitoring (CGM) devices driven by lifestyle ...

The devices have surged in popularity among people without diabetes, but a study suggests reality may not match the hype.View ...

Biolinq announced today that it received FDA de novo clearance for its lead product, the Biolinq Shine wearable biosensor.

The American Diabetes Association commended Alabama Medicaid for its recent decision to expand coverage for continuous glucose monitoring (CGM) technology.

The Food and Drug Administration has granted de novo classification to a continuous glucose monitor made by Biolinq for ...

To hear some of them tell it, the companies selling continuous glucose monitors have stumbled upon a heretofore unknown quirk of human biology. Seemingly healthy people, many of these companies argue, ...

Please provide your email address to receive an email when new articles are posted on . McKee and colleagues conducted a retrospective survey of adults attending the Washington ...